NCT06134011

Brief Summary

In the study, the investigators obtained gastric cancer tissues from 480 gastric cancer patients who had undergone surgery at the Zhejiang Cancer Hospital's biospecimen bank between 2012-2019, and obtained relevant clinical information. The gastric cancer tissues were subjected to transcriptomic, metabolomic and other multi-omics testing, and analyzed for the metabolic changes of gastric cancer, and proposed to discover relevant therapeutic targets.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
480

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 10, 2023

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

November 9, 2023

Completed
9 days until next milestone

First Posted

Study publicly available on registry

November 18, 2023

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 10, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 10, 2024

Completed
Last Updated

November 18, 2023

Status Verified

November 1, 2023

Enrollment Period

1 year

First QC Date

November 9, 2023

Last Update Submit

November 15, 2023

Conditions

Gastric CancerMulti-omicsDiagnosis

Outcome Measures

Primary Outcomes (1)

  • The differences of the metabolism information

    The differences of the metabolism information between gastric cancer tissues and non-cancerous gastric cancer tissues. These data included Metabolizing enzyme mRNA expression and metabolite content.

    through study completion, an average of 6 months

Study Arms (2)

Cancer tissues

Other: Without any intervention

Normal adjacent tissues

Other: Without any intervention

Interventions

Without any interventionOTHER

There were no special interventions for the two groups.

Cancer tissuesNormal adjacent tissues

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

These cases have histologically or cytologically confirmed gastric cancer and there are no other tumors

You may qualify if:

  • ≤age≤80
  • Histologically or cytologically confirmed gastric cancer
  • Undergo surgery for radical or palliative gastric cancer (both open and laparoscopic)
  • Patients with survival follow-up information

You may not qualify if:

  • Two or more kinds of malignant tumors at the same time
  • Incomplete or missing case information
  • Preoperative diagnosis of residual gastric cancer

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)

Hangzhou, Zhejiang, China

Location

Related Publications (3)

  • Li S, Yuan L, Xu ZY, Xu JL, Chen GP, Guan X, Pan GZ, Hu C, Dong J, Du YA, Yang LT, Ni MW, Jiang RB, Zhu X, Lv H, Xu HD, Zhang SJ, Qin JJ, Cheng XD. Integrative proteomic characterization of adenocarcinoma of esophagogastric junction. Nat Commun. 2023 Feb 11;14(1):778. doi: 10.1038/s41467-023-36462-8.

    PMID: 36774361RESULT

  • Shi W, Wang Y, Xu C, Li Y, Ge S, Bai B, Zhang K, Wang Y, Zheng N, Wang J, Wang S, Ji G, Li J, Nie Y, Liang W, Wu X, Cui J, Wang Y, Chen L, Zhao Q, Shen L, He F, Qin J, Ding C. Multilevel proteomic analyses reveal molecular diversity between diffuse-type and intestinal-type gastric cancer. Nat Commun. 2023 Feb 14;14(1):835. doi: 10.1038/s41467-023-35797-6.

    PMID: 36788224RESULT

  • Wang J, Kunzke T, Prade VM, Shen J, Buck A, Feuchtinger A, Haffner I, Luber B, Liu DHW, Langer R, Lordick F, Sun N, Walch A. Spatial Metabolomics Identifies Distinct Tumor-Specific Subtypes in Gastric Cancer Patients. Clin Cancer Res. 2022 Jul 1;28(13):2865-2877. doi: 10.1158/1078-0432.CCR-21-4383.

    PMID: 35395077RESULT

MeSH Terms

Conditions

Stomach NeoplasmsDisease

Condition Hierarchy (Ancestors)

Gastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesStomach DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
OTHER
Target Duration
10 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Secretary of the party committee

Study Record Dates

First Submitted

November 9, 2023

First Posted

November 18, 2023

Study Start

September 10, 2023

Primary Completion

September 10, 2024

Study Completion

September 10, 2024

Last Updated

November 18, 2023

Record last verified: 2023-11

Data Sharing

IPD Sharing
Will not share

This study does not involve drug clinical trials but focuses on ensuring the confidentiality of patient information. To protect patient privacy, a coding system was used instead of real names when entering patient information such as names and ages. Each patient was assigned a study identification number upon enrollment. Throughout the entire study, only the main researchers in the research team have the authority to access the true personal data of patients obtained from the electronic database (such as names and ages), and it is strictly prohibited to circulate or share this information. During the publication of the research article, the main researchers in the research team will use sample coding to replace patient privacy information (such as names) to achieve de-identification. Additionally, the protection of personal information for study participants must be maintained throughout the entire research process, and it is strictly forbidden to circulate or leak such information.

Locations

CN(1)